Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it has incorporated its Volcano catheter-based imaging and measurement solutions for minimally invasive diagnostics and treatment of cardiovascular and other disease, into its robust portfolio of interventional cardiology solutions in Canada.
“We are committed to delivering innovative solutions for our customers in Canada and the patients they serve,” said Iain Burns, President and CEO of Philips Canada. “The inclusion of our Volcano products will provide our customers with better access to all of the integrated technologies and specialized expertise across Philips’ entire Image Guided Therapy portfolio. Offering our customers these integrated solutions helps us achieve our goal of equipping them with tools that can improve their patients’ care.”
Philips has an existing rich portfolio of interventional imaging equipment, navigation tools and services, and a sizeable customer base, including 85% of Canadian hospitals who have chosen Philips cardiology solutions. Philips’ advanced interventional imaging systems and navigation tools provide the visual maps that allow the clinician to guide thin, tube-shaped instruments called catheters through the body to the area of interest and perform the minimally invasive treatment. In image-guided treatments of the heart and blood vessels, there is increased clinical evidence which demonstrates that the use of imaging and measurement catheters in conjunction with interventional x-ray imaging helps improve procedural outcomes.
Through its Volcano product portfolio, Philips is a world leader in catheter-based imaging and measurements like IVUS (Intravascular Ultrasound) catheters that are capable of producing ultrasound images of the interior blood vessels and FFR/iFR (Fraction Flow Reserve) technologies that are used to assess the blood pressure. These solutions complement Philips’ portfolio of interventional x-ray and ultrasound imaging equipment, navigation systems, software and services; together they enable confident diagnosis and treatment.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips’ health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 69,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161004005314/en/Business Wire
Last updated on: 04/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.